Price
$12.12+5.57%Social Signal Score
Analyst Ratings
32 analystsRevenue
$836.00M-16.11%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel T. Scavilla
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 14,000
- Beta
- 0.86
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 0.71
Financials
Revenue
$836.00M-16.1%Net Income
$-2.00M-101.9%EBITDA
$133.00M-46.0%Free Cash Flow
$0.00-100.0%EPS (diluted)
$-0.01-102.2%Shares Outstanding (diluted)
199.20M-14.9%Operating Expenses
$405.00MCash & Debt
$195.00MReturn of Capital
$13.00MRevenue by Segment (annual)
$3.92BDividend per Share
$0.16Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.68B | $-598.00M | $-3.00 |
| 2024 | $3.79B | $-910.00M | $-4.48 |
| 2023 | $3.96B | $-132.00M | $-0.62 |
| 2022 | $3.92B | $-950.00M | $-4.41 |
| 2021 | $4.23B | $411.00M | $1.88 |
| 2020 | $3.34B | $-73.00M | $-0.38 |
| 2019 | $4.02B | $256.00M | $1.18 |
| 2018 | $3.99B | $-1.01B | $-4.51 |
| 2017 | $3.99B | $-1.55B | $-6.86 |
| 2016 | $3.75B | $429.90M | $1.97 |
| 2015 | $2.67B | $251.20M | $1.79 |
| 2014 | $2.92B | $322.85M | $2.28 |
| 2013 | $2.95B | $313.19M | $2.20 |
| 2012 | $2.93B | $314.21M | $2.22 |
Valuation
XRAYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
45-35.71%Social Signal Score
Mentions (13)
- Newsfool.com·6d ago·Neutral
Dentsply Sirona: 3 Key Takeaways for Long-Term Investors Management reduced full-year 2026 sales guidance to approximately $3.5 billion. Wellspect Healthcare revenue grew 10% year over year to $92 million.
View source ↗ - Newsseekingalpha.com·15d ago·Positive
DENTSPLY SIRONA Inc. (XRAY) Q3 2026 Earnings Call Transcript DENTSPLY SIRONA Inc. ( XRAY ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Suzanne Hatcher Daniel Scavilla - President, CEO, Interim Principal Financial Officer & Director John Fortson - Executive VP & CFO Conference Call Participants Allen Lutz - BofA Securities, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated,…
View source ↗ - Newsmarketbeat.com·16d ago·Negative
DENTSPLY SIRONA Q3 Earnings Call Highlights DENTSPLY SIRONA NASDAQ: XRAY lowered its full-year earnings outlook after third-quarter sales fell across its dental businesses, as pressure from European distributor inventory reductions, the Middle East conflict and higher freight costs offset progress in parts of its U.S. operations.
View source ↗ - Newszacks.com·16d ago·Negative
XRAY Stock Declines as Q3 Earnings & Sales Miss Estimates, Outlook Cut DENTSPLY SIRONA's Q3 sales decline 7.6% amid dental weakness, while Wellspect growth provides support. The company lowers its 2026 outlook.
View source ↗ - Newszacks.com·17d ago·Neutral
Dentsply (XRAY) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for Dentsply (XRAY) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newszacks.com·17d ago·Negative
Dentsply International (XRAY) Q3 Earnings and Revenues Miss Estimates Dentsply International (XRAY) came out with quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.37 per share a year ago.
View source ↗ - Newszacks.com·18d ago·Negative
DENTSPLY SIRONA to Post Q3 Earnings: What's in Store for the Stock? DENTSPLY SIRONA faces Q3 earnings pressure from weak dental demand, tariff costs and segment challenges, while Wellspect's growth may offer some relief.
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
…hird Quarter 2026 Conference Call on November 5 CHARLOTTE, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, November 5, 2026, at 4:30 p.m. EST to review its third quarter 2026 financial results. Financial earnings materials will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com…
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio MÖLNDAL, Sweden, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wellspect HealthCare today announced that the Surity™ portfolio, including the Surity™ Urinary Management System and Surity™ Female and Male External Catheters, may be covered by traditional Medicare for eligible beneficiaries when medically necessary. This milestone represents an important step in expanding access and reducing barriers to
View source ↗ - Newszacks.com·66d ago·Neutral
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.
View source ↗ - Newszacks.com·75d ago·Positive
XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.
View source ↗ - Newsprnewswire.com·95d ago·Positive
New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence New system completes the Surity™ portfolio of external catheters for both men and women Integrates into daily routines to help support management of urinary incontinence at home Designed to operate quietly overnight, new Surity™ System helps minimize nighttime interruptions to support comfort and rest MÖLNDAL, Sweden, Aug. 19, 2026 /PRNewswire/ -- Wellspect Hea
View source ↗ - Newsmarketbeat.com·107d ago·Negative
DENTSPLY SIRONA Q2 Earnings Call Highlights DENTSPLY SIRONA NASDAQ: XRAY reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europe.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $0.29 per share
Typical surprise -3.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.29 vs $0.31miss
- Thu, Aug 6$0.52 vs $0.35beat
- Tue, May 5$0.27 vs $0.28miss
- Thu, Feb 26$0.27 vs $0.28miss
- Thu, Nov 6$0.37 vs $0.45miss
- Thu, Aug 7$0.52 vs $0.50beat
Estimates and results for XRAY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by XRAY officers and directors.
- Bought
- $1.6m
- Sold
- $916k
11 trades
1 trade
- Hosein Clydebought
- Gladden Brian Tbought
- Mazelsky Jonathan Jaybought
- Mckeon Brian Pbought
- Holden Betsy Dbought
- Barber Michael Jbought
- Lucier Gregory Tbought
- Forbes James Dbought
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Feb 12, 2025 (35d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Feb 12, 2025 (36d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2022 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (18d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed May 25, 2022 (36d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed May 25, 2022 (36d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed May 6, 2022 (25d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 6, 2022 (15d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 17, 2022 (43d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 17, 2022 (30d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 17, 2022 (43d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 17, 2022 (30d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 23, 2022 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 23, 2022 (26d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed Jan 16, 2022 (42d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed Jan 16, 2022 (44d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed May 21, 2019 (12d later)Buy$1,001 - $15,000
- Dean Phillipshouse · MN03 · disclosed Feb 18, 2019 (45d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
